September 2016 edition

Our September edition is available to read now. The issue features companies and insight articles focused on next-generation antibodies, platform biotech technologies and the rapidly moving area of immuno-oncology.

Sep 05, 2016

Read the newly released September edition of BioPharma Dealmakers.

Browse through the companies working in the antibodies, regenerative medicine and immuno-oncology fields and looking for partnerships -


Aspyrian Therapeutics

BeyondSpring Pharmaceuticals

Crescendo Biologics




GroK Technologies


MAB Discovery

MS Ventures

Oslo Cancer Cluster


Precision Biosciences


This issue also features our three in-depth articles that chart the checkpoint inhibitors in the rapidly growing immuno-oncology field, follow the progress of bi-specific antibodies and highlights the new-found independence of platform biotechs.

Charting checkpoint inhibitors

Bispecific antibody platforms spawn dealmaking boom

Platform biotechs bring out pharma’s creative side

Raveena Bhambra

Editor, BioPharma Dealmakers , Nature Publishing Group

Hello all, I am the Editor of BioPharma Dealmakers, a quarterly publication that assists companies in identifying potential partners in the pharmaceutical and biotechnology industry and appears in both Nature Biotechnology and Nature Reviews Drug Discovery. I am very passionate about the biopharma industry and have over 12 years of experience of working in the field, specifically in dealmaking, partnering and licensing. In my previous roles I have conducted partner searches identifying both products/technologies and partners for clients, and have edited and written dealmaking-focused reports.

No comments yet.